Patent ID: 11857546
Assignee: AROG PHARMACEUTICALS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method for treating a subject suffering from a hematological malignancy, the method comprising the steps of:
determining whether the subject has increased FLT3 tyrosine kinase activity by:
obtaining or having obtained a biological sample from the patient; and
performing or having performed an assay on the biological sample to determine if the patient has a gene mutation in the FLT3 gene, a change in the kinase activity of the FLT3 tyrosine kinase, overexpression of the FLT3 tyrosine kinase, or a change in a phenotype or genotype of the FLT3 tyrosine kinase, wherein the mutation in the FLT3 gene or change in phenotype or genotype of FLT3 is a resistance-conferring mutation selected from a missense mutation occurring in at least one of amino acid residues K429, A627, N676, A680, F691, Y693, G697, D698, N701, D835, N841, Y842, A848 present alone or in combination with a FLT3-ITD mutation;
treating the subject with a first tyrosine kinase inhibitor; and
if the patient is refractory to or relapses after treatment with the first tyrosine kinase inhibitor, and the patient has a gene mutation in FLT3; a change in the kinase activity of FLT3, overexpression of FLT3, or a change in the phenotype or genotype of FLT3 tyrosine kinase, then discontinuing administration of the first tyrosine kinase inhibitor and internally administering crenolanib to the patient in an effective amount to reduce a hematological malignancy burden or to prevent proliferative disease the hematological malignancy progression.